Salokangas R K, Syvälahti E, Lehtinen I
Methods Find Exp Clin Pharmacol. 1983;5(4):263-9.
The study dealt with the occurrence of dyskinetic symptoms and disturbances in eye movements in 15 young schizophrenic patients and the effect on these disturbances of anticholinergic antiparkinsonian medication administered during neuroleptic medication maintained at a stable level. The onset of illness had occurred at a younger age in the dyskinetic patients than in the others, and they had received larger amounts of high-dose neuroleptic medication, which, however, equalled an average daily dose of only 331 mg of chlorpromazine during an average of 2 1/2 years; thus, dyskinetic symptoms can appear in young patients even during a fairly short and moderate course of medication with high-dose neuroleptics. Patients with a disturbance in smooth pursuit movement were clinically less disturbed than the others; depression, however, was more common among them. During therapy with an anticholinergic antiparkinsonian drug (Biperiden) depression worsened in patients with eye movement disturbance, while in other patients it was alleviated. The results, in fact, indicated that on the basis of disturbances in smooth pursuit movement it might be possible to distinguish among schizophrenia-group patients a depressively coloured marginal group in whom the reaction to anticholinergic medication differs from that found for patients in the nuclear-schizophrenia group.
该研究探讨了15名年轻精神分裂症患者的运动障碍症状和眼球运动紊乱情况，以及在抗精神病药物维持在稳定水平期间给予抗胆碱能抗帕金森药物对这些紊乱的影响。运动障碍患者的发病年龄比其他患者更小，他们接受了更大剂量的高剂量抗精神病药物治疗，然而，在平均2.5年的时间里，这些药物的平均日剂量仅相当于331毫克氯丙嗪；因此，即使在使用高剂量抗精神病药物进行相对较短且适度的疗程中，年轻患者也可能出现运动障碍症状。平滑追踪运动有障碍的患者在临床上比其他患者受干扰程度小；然而，抑郁症在他们当中更为常见。在使用抗胆碱能抗帕金森药物（安克痉）治疗期间，有眼球运动障碍的患者抑郁症加重，而其他患者的抑郁症则得到缓解。事实上，结果表明，基于平滑追踪运动的紊乱，有可能在精神分裂症组患者中区分出一个有抑郁色彩的边缘组，该组对抗胆碱能药物的反应与核心精神分裂症组患者不同。
